Drug
Panitumumab Folfiri
Panitumumab Folfiri: highest development phase Phase 2, developed by Amgen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Amgen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Panitumumab + FOLFIRI NCT01144195 | Phase 2 | Metastatic Colorectal Cancer |
Latest
No recent events.
Follow Panitumumab Folfiri on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.